417 related articles for article (PubMed ID: 1319000)
1. Detection of functional ovarian hyperandrogenism in women with androgen excess.
Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
[TBL] [Abstract][Full Text] [Related]
2. Source localization of androgen excess in adolescent girls.
Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
[TBL] [Abstract][Full Text] [Related]
3. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
4. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL; Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
Rosenfield RL; Ehrmann DA; Barnes RB; Sheikh Z
Ann N Y Acad Sci; 1993 May; 687():162-81. PubMed ID: 8323171
[TBL] [Abstract][Full Text] [Related]
6. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
7. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency.
Barnes RB; Ehrmann DA; Brigell DF; Rosenfield RL
J Clin Endocrinol Metab; 1993 Feb; 76(2):450-5. PubMed ID: 8381802
[TBL] [Abstract][Full Text] [Related]
8. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
9. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
Barnes RB; Rosenfield RL; Ehrmann DA; Cara JF; Cuttler L; Levitsky LL; Rosenthal IM
J Clin Endocrinol Metab; 1994 Nov; 79(5):1328-33. PubMed ID: 7962325
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women.
Fanta M; Cibula D; Vrbíková J
Gynecol Endocrinol; 2008 Mar; 24(3):154-7. PubMed ID: 18335331
[TBL] [Abstract][Full Text] [Related]
11. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
12. Ultrasonographic appearance of polycystic ovaries is associated with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment.
Suikkari AM; MacLachlan V; Montalto J; Calderon I; Healy DL; McLachlan RI
Hum Reprod; 1995 Mar; 10(3):513-9. PubMed ID: 7782424
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
Andreyko JL; Monroe SE; Jaffe RB
J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
[TBL] [Abstract][Full Text] [Related]
14. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
15. Ovarian 17-ketosteroid reductase deficiency as a possible cause of polycystic ovarian disease.
Toscano V; Balducci R; Bianchi P; Mangiantini A; Sciarra F
J Clin Endocrinol Metab; 1990 Aug; 71(2):288-92. PubMed ID: 2166066
[TBL] [Abstract][Full Text] [Related]
16. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism.
Carmina E; Rosato F; Jannì A; Rizzo M; Longo RA
J Clin Endocrinol Metab; 2006 Jan; 91(1):2-6. PubMed ID: 16263820
[TBL] [Abstract][Full Text] [Related]
17. Pituitary-ovarian responses to leuprolide acetate testing in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Ghizzoni L; Virdis R; Vottero A; Cappa M; Street ME; Zampolli M; Ibañez L; Bernasconi S
J Clin Endocrinol Metab; 1996 Feb; 81(2):601-6. PubMed ID: 8636275
[TBL] [Abstract][Full Text] [Related]
18. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences.
Falsetti L; Gambera A; Andrico S; Sartori E
Gynecol Endocrinol; 2002 Aug; 16(4):275-84. PubMed ID: 12396556
[TBL] [Abstract][Full Text] [Related]
19. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F; Hatala DA; Speroff L
Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
[TBL] [Abstract][Full Text] [Related]
20. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.
Pall M; Azziz R; Beires J; Pignatelli D
Fertil Steril; 2010 Jul; 94(2):684-9. PubMed ID: 19726039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
